Core Insights - The cosmetics sector experienced a slight increase of 0.31% on October 14, with Shanghai Jahwa leading the gains [1] - The Shanghai Composite Index closed at 3865.23, down 0.62%, while the Shenzhen Component Index closed at 12895.11, down 2.54% [1] Company Performance - Shanghai Jahwa (600315) closed at 26.59, up 5.10%, with a trading volume of 102,700 shares and a transaction value of 270 million yuan [1] - Lafang (603630) closed at 24.65, up 4.05%, with a trading volume of 90,200 shares and a transaction value of 221 million yuan [1] - Qingdao Kingway (002094) closed at 7.97, up 1.92%, with a trading volume of 413,400 shares and a transaction value of 329 million yuan [1] - Other notable performers include Bawei (920123) at 17.83 (+1.54%) and Jinsong New Materials (300849) at 13.53 (+0.97%) [1] Fund Flow Analysis - The cosmetics sector saw a net outflow of 13.28 million yuan from institutional investors, while retail investors experienced a net outflow of 46.69 million yuan [2] - Conversely, speculative funds recorded a net inflow of 59.98 million yuan [2] Individual Stock Fund Flow - Shanghai Jahwa had a net inflow of 29.86 million yuan from institutional investors, while retail investors saw a net outflow of 24.90 million yuan [3] - Lafang recorded a net inflow of 21.89 million yuan from institutional investors, with retail investors experiencing a net outflow of 21.61 million yuan [3] - Qingdao Kingway had a net inflow of 16.80 million yuan from institutional investors, while retail investors saw a net outflow of 18.67 million yuan [3]

Core Viewpoint - Betta Pharmaceuticals (300957.SZ) aims to enhance its comprehensive competitiveness and profitability by becoming a limited partner in a new investment fund focused on the healthcare sector [1] Group 1: Investment Details - The company will invest 50 million yuan as a limited partner in the Wuxi Jinyu Maowu Medical Health Industry Investment Partnership, holding a 5% share in the fund [1] - The fund is established in collaboration with several partners, including Wuxi Jinjiao Investment Partnership and Jiangsu Wuxi Biomedical Industry Special Mother Fund [1] Group 2: Investment Focus - The partnership will primarily invest in areas such as consumer healthcare, quality improvement of national health, pharmaceuticals (including synthetic biology and innovative drugs), medical devices, supportive medical industries, and AI-driven pharmaceuticals [1]

Core Viewpoint - Betta Pharmaceuticals (300957.SZ) aims to enhance its comprehensive competitiveness and profitability by becoming a limited partner in a new investment fund focused on the healthcare industry [1] Group 1: Investment Details - The company will invest 50 million yuan as a limited partner in the Wuxi Jinyu Maowu Medical Health Industry Investment Partnership, holding a 5% share in the fund [1] - The fund is established in collaboration with several partners, including Wuxi Jinjiao Investment Partnership and Jiangsu Wuxi Biomedical Industry Special Mother Fund [1] Group 2: Investment Focus - The partnership will primarily invest in sectors such as consumer healthcare, quality improvement of national health, pharmaceuticals (including synthetic biology and innovative drugs), medical devices, supportive medical industries, and AI-driven pharmaceuticals [1]

Core Viewpoint - Betaini (300957) has signed a partnership agreement with Wuxi Jinyu Maowu Medical Health Industry Investment Partnership, committing 50 million yuan as a limited partner, acquiring a 5% stake in the fund [1] Investment Details - The investment will focus on sectors such as consumer healthcare, national health quality improvement (including wellness, medical aesthetics, special medical foods, and functional foods), pharmaceuticals (including synthetic biology and innovative drugs), medical devices, supportive medical industries, and AI in pharmaceuticals [1]

Core Viewpoint - The company, Betaini (300957.SZ), has signed a partnership agreement with Wuxi Jinyu Mao Medical Health Industry Investment Partnership (Limited Partnership), committing to invest 50 million yuan, which will give the company a 5% stake in the fund [1] Investment Details - The investment will be managed by Jinyu Mao Investment Management Co., Ltd. [1] - The partnership primarily focuses on sectors such as consumer healthcare, national health quality improvement (including wellness, medical aesthetics, special medical foods, and functional foods), pharmaceuticals (including synthetic biology and innovative drugs), medical devices, supportive medical industries, and AI in pharmaceuticals [1]

Core Viewpoint - Betta Pharmaceuticals (300957.SZ) has signed a partnership agreement with Wuxi Jinyu Maowu Medical Health Industry Investment Partnership, committing 50 million yuan as a limited partner, acquiring a 5% stake in the fund [1] Investment Focus - The partnership will primarily invest in sectors such as consumer healthcare, national health quality improvement (including wellness, medical aesthetics, special medical foods, and functional foods), pharmaceuticals (including synthetic biology and innovative drugs), medical devices, supportive medical industries, and AI-driven pharmaceuticals [1]

根据《深圳证券交易所创业板股票上市规则》以及《公司章程》等相关规定， 公司本次投资不构成关联交易，不构成《上市公司重大资产重组管理办法》规定的 重大资产重组。本次投资交易金额未达到公司最近一期经审计净资产的10%，本次 投资事项的审批在总经理权限范围内，无需提交董事会或股东会审议。 （一）基金管理人：金雨茂物投资管理股份有限公司 证券代码：300957 证券简称：贝泰妮 公告编号：2025-039 成立时间：2009年7月9日 统一社会信用代码：91320000692122075A 法定代表人：段小光 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在任何虚 假记载、误导性陈述或者重大遗漏。 为了进一步提升云南贝泰妮生物科技集团股份有限公司（以下简称"公司"） 综合竞争力和盈利能力、把握战略合作机会，公司拟作为有限合伙人，与无锡金鹫 投资合伙企业（有限合伙）（以下简称"金鹫投资"、"普通合伙人"）、江苏无 锡生物医药产业专项母基金（有限合伙）、江阴高新区金融投资有限公司、江阴市 金融投资有限公司、南京今茂管理咨询合伙企业（有限合伙）、泉州市蠡湖至真投 资有限公司、马鞍山慈湖创业投资合伙企业（有限合伙） ...

Core Insights - The podcast "Business is Like This" has returned, focusing on sustainable practices in companies, with a highlight on Betaini Group's recognition in the 2025 Sustainable Practice Annual Case by Green Point China [1] - The episode emphasizes "biodiversity" as a key term in corporate sustainability, which includes the protection of various life forms and their environments [1] - The China Securities Regulatory Commission will require listed companies to disclose biodiversity protection efforts in their sustainability reports starting in 2026 for certain key companies [1] Company Focus - Betaini Group is recognized as a leader among Chinese companies for integrating biodiversity protection into its core business, particularly through sourcing skincare ingredients from the rich biodiversity of Yunnan [2] - The company has initiated actions to protect local biodiversity while developing valuable skincare raw materials from the Haba Snow Mountain area in Yunnan [2]

Investment Rating - The report gives a "Buy" rating for the cosmetics and medical beauty industry, particularly highlighting the potential of specific companies like Water Sheep Co., Ltd. [13] Core Insights - The cosmetics and medical beauty sector has underperformed the market recently, with the Shenwan Beauty Care Index rising by 1.3% from September 29 to October 10, 2025, which is lower than the overall market performance [3][4] - The upcoming Tmall Double 11 event is expected to boost sales, with domestic brands actively participating with competitive discounts [8] - Water Sheep Co., Ltd. is identified as a leading technology-driven beauty company, with stable revenue projections and improving profit margins [9][10] Summary by Sections Industry Performance - The cosmetics and medical beauty sector has shown weaker performance compared to the market, with the Shenwan Cosmetics Index increasing by 1.2%, lagging behind the Shenwan A Index by 0.4 percentage points [3][4] - The top-performing stocks in the sector include Jiaheng Home Care (+35.0%), Yiyi Co., Ltd. (+18.6%), and Yanjing Co., Ltd. (+15.6%) [5] Upcoming Events - Tmall's Double 11 sales event is set to begin on October 15, 2025, with major domestic brands like Proya and Maogeping expected to participate actively [8] Company Focus: Water Sheep Co., Ltd. - Water Sheep Co., Ltd. has a dual business model of proprietary and CP agency brands, with projected revenues stabilizing between 4 to 5 billion yuan from 2021 to 2024 [9] - The company is expected to achieve net profits of 258 million, 331 million, and 398 million yuan for the years 2025, 2026, and 2027, respectively, reflecting significant growth [10][13] Market Trends - The overall retail sales of cosmetics in August 2025 grew by 5.1%, indicating a recovery in consumer demand [17] - The domestic market is seeing a shift in market share, with local brands gaining ground against international competitors [25] E-commerce Insights - Data shows that domestic brands are performing well on platforms like Douyin and Tmall, with significant growth in GMV for brands like Proya and Maogeping [14][15] Company Developments - Proya has filed for an IPO in Hong Kong, with stable revenue growth and a strong online presence [19] - The report highlights the strategic moves of various companies, including partnerships and new product launches, to enhance their market positions [24][23]

Investment Rating - The report maintains an "Accumulate" rating for the retail industry [1] Core Views - The National Day and Mid-Autumn Festival holiday saw a significant increase in domestic travel, with 888 million trips taken, a 16% increase compared to the previous year, and total spending reaching 809 billion yuan, up 15% [3][8] - Strong travel and family visit intentions were noted, with self-driving trips accounting for 80% of travel during the holiday period [12] - The report highlights a continued increase in inbound and outbound tourism, with a 11.5% year-on-year growth in border inspection personnel [14] - Key tourist attractions experienced a rise in visitor numbers, with notable increases at Huangshan, Jiuhua Mountain, and Emei Mountain, suggesting robust demand in the tourism sector [15] Summary by Sections 1. Industry Views This Week - The report emphasizes the positive outlook for the tourism sector during the National Day and Mid-Autumn Festival, with significant increases in both travel numbers and spending [8] 2. Market Review This Week - The retail index saw a decline of 0.40% from October 9 to October 10, while the overall market performance varied across different indices [16][18] 3. Valuation Table of Sub-Industries - The report includes a detailed valuation table for various companies within the retail sector, providing insights into market capitalization, closing prices, and projected earnings [22][23]